Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form

被引:377
作者
Lee, HJ
Choi, C
Lee, SJ
机构
[1] Parkinsons Inst, Sunnyvale, CA 94089 USA
[2] Chonnam Natl Univ, Med Sch, Dept Pathol, Kwangju 501190, South Korea
关键词
D O I
10.1074/jbc.M107045200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha-Synuclein exists as at least two structural isoforms: a helix-rich, membrane-bound form and a disordered, cytosolic form. Here, we investigated the role of membrane-bound alpha-synuclein in the aggregation process. In a cell-free system consisting of isolated brain fractions, spontaneous and progressive aggregation of alpha-synuclein was observed in membranes starting at day 1, whereas no aggregation was observed in the cytosolic fraction in a 3-day period. The addition of antioxidants reduced the aggregation in the membrane fraction, implicating the role of oxidative modifications. When excess cytosolic alpha-synuclein was added to brain membranes, the rate of aggregation was increased, while the lag time was unaffected. Incorporation of cytosolic alpha-synuclein into membrane-associated aggregates was demonstrated by fractionation and co-immunoprecipitation experiments. In our recent study, we showed that mitochondrial inhibitors such as rotenone, induced alpha-synuclein aggregation in cells. In the present study using rotenone-treated cells, the earliest appearance of alpha-synuclein oligomeric species was observed in membranous compartments. Furthermore, alpha-synuclein-positive inclusions were co-stained with DiI, a membrane-partitioning fluorescent dye, confirming the presence of lipid components in alpha-synuclein aggregates. These results suggest that membrane-bound alpha-synuclein can generate nuclei that seed the aggregation of the more abundant cytosolic form.
引用
收藏
页码:671 / 678
页数:8
相关论文
共 67 条
[1]   Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system [J].
Abeliovich, A ;
Schmitz, Y ;
Fariñas, I ;
Choi-Lundberg, D ;
Ho, WH ;
Castillo, PE ;
Shinsky, N ;
Verdugo, JMG ;
Armanini, M ;
Ryan, A ;
Hynes, M ;
Phillips, H ;
Sulzer, D ;
Rosenthal, A .
NEURON, 2000, 25 (01) :239-252
[2]   NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy [J].
Arima, K ;
Uéda, K ;
Sunohara, N ;
Arakawa, K ;
Hirai, S ;
Nakamura, M ;
Tonozuka-Uehara, H ;
Kawai, M .
ACTA NEUROPATHOLOGICA, 1998, 96 (05) :439-444
[3]   Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies [J].
Arima, K ;
Uéda, K ;
Sunohara, N ;
Hirai, S ;
Izumiyama, Y ;
Tonozuka-Uehara, H ;
Kawai, M .
BRAIN RESEARCH, 1998, 808 (01) :93-100
[4]  
Baba M, 1998, AM J PATHOL, V152, P879
[5]  
Braak E, 2001, ACTA NEUROPATHOL, V101, P195
[6]   The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease [J].
Clayton, DF ;
George, JM .
TRENDS IN NEUROSCIENCES, 1998, 21 (06) :249-254
[7]   Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
BIOCHEMISTRY, 2000, 39 (10) :2552-2563
[8]   Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease:: Implications for pathogenesis and therapy [J].
Conway, KA ;
Lee, SJ ;
Rochet, JC ;
Ding, TT ;
Williamson, RE ;
Lansbury, PT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (02) :571-576
[9]   Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease [J].
Conway, KA ;
Harper, JD ;
Lansbury, PT .
NATURE MEDICINE, 1998, 4 (11) :1318-1320
[10]   Stabilization of α-synuclein secondary structure upon binding to synthetic membranes [J].
Davidson, WS ;
Jonas, A ;
Clayton, DF ;
George, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (16) :9443-9449